Back to results
US 12,569,556 B2Granted
Aluminum based adjuvants for tolerogenic vaccination
AssigneeEast Carolina University
InventorMark D. Mannie
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.
Claims14
A composition comprising:
- (a) an autoimmune antigen selected from the group consisting of proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin-associated oligodendrocytic basic protein and cardiac myosin, or portions thereof, wherein the portions comprise the encephalitogenic determinant portion;
- (b) an anti-inflammatory cytokine that is interferon alpha or interferon beta;
- and
- (c) an aluminum-based adjuvant which is noncovalently bound to both the autoimmune antigen and the anti-inflammatory cytokine,
- wherein the autoimmune antigen and the interferon alpha or interferon beta are not covalently linked.
2 more elements
A composition comprising:
- (a) myelin oligodendrocyte glycoprotein (MOG),
- (b) interferon beta;
- and
- (c) an aluminum-based adjuvant which is bound to both the autoimmune antigen and the anti-inflammatory cytokine,
- wherein the MOG and the interferon beta are not covalently linked.
2 more elements
Dependencies are inferred from the claim text.